North America Human Microbiome Market Trends and Analysis by 2025

North America Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs, and Supplements), Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders, and Others), Application (Therapeutics and Diagnostics), and Country

Historic Data: 2015-2016 | Base Year: 2017 | Forecast Period: 2018-2025
  • Status : Published
  • Report Code : TIPRE00003319
  • Category : Life Sciences
  • No. of Pages : 152
  • Available Report Formats : pdf-format excel-format
  • Last update date : February 27, 2019
North America Human Microbiome Market Trends and Analysis by 2025
Report Date: February 27, 2019   |   Report Code: TIPRE00003319 Email: sales@theinsightpartners.com

2017 Market Size

US$ 113.88 Mn

Base year value

2025 Forecast

US$ 446.39 Mn

Projected by 2025

CAGR 2018-2025

21.5 %

Growth rate

Addressable Market

US$ 2,412.74 Mn

(2018-2025)

The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017. The market is estimated to grow with a CAGR of 21.5% from 2018-2025.



The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome and next-generation sequencing. Whereas, strict government guidelines and lack of knowledge and detailed examination is likely to have a negative impact on the growth of the market in the coming years.

Humans are never alone as they coexist with the diverse microbial species that live within and upon humans. From recent studies it has been very clear that this microbial community is essentially another organ of the body that plays a crucial role in human physiology and disease. Several basic and translational research efforts have been initiated to focus on deciphering mechanisms of microbiome function and how it benefits the human health. Many human medical conditions (like inflammatory bowel diseases and obesity) have been closely associated with or are thought to be influenced by (asthma and diabetes) the composition of the gut microbial community. Many efforts are taken to alter the gut microbiome to eradicate several diseases. Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health.

The Human Microbiome Project of the National Institutes of Health in the United States and related international efforts are defining the varieties of a normal microbiome, studying how changes in the microbiota relate to disease. Large governmental research initiatives including the Human Microbiome Project in the U.S. have accelerated research on the human microbiome.

Also, many companies are designing and developing many microbiome therapies. For instance, Rebiotix Inc. has developed Microbiota Restoration Therapy (MRT) drug platform which is the drug platform for delivering healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

US is anticipated to lead the adoptions of Human microbiome across the North American region through the forecast period. The application of the human microbiome are beneficial for various treatment areas such as cancer, Inflammatory Bowel Disease (IBD), diabetes, autoimmune diseases and more. To be specific with the applications of the human microbiome, it plays important role in the developments in wide range of diseases and disorders which includes cardiovascular disease, cancer, autoimmune, neurological disorders and more. Therefore, various programs are being organized in the country to grow the awareness of probiotics and prebiotics in order to enhance the human microbiome.

For instance, in February 2018, the 3rd Annual North America Microbiome Congress was held in San Diego, by Kisaco Research that focused on 5 microbiome niches such as the gut, lung, oral, skin and vaginal and provided latest insights on microbiome research, clinical trials and collaborative partnerships.

Thus, owing to the above mentioned factors the market for the human microbiome is likely to grow with a significant growth rate in the coming forecast years.

Mexico Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)

h91Jnj4lflNdwAAAABJRU5ErkJggg==
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.


NORTH AMERICA HUMAN MICROBIOME- MARKET SEGMENTATION

By Product


• Probiotics
• Foods
• Prebiotics
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements

NORTH AMERICA HUMAN MICROBIOME- MARKET SEGMENTATION


By Disease


• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Others

NORTH AMERICA HUMAN MICROBIOME- MARKET SEGMENTATION


By Application


• Therapeutics
• Diagnostics

By Country


• U.S.
• Canada
• Mexico

Companies Mentioned


• Enterome
• MicroBiome Therapeutics, LLC
• Rebiotix Inc.
• Yakult Honsha Co., Ltd.
• Osel Inc.
• Vedanta Biosciences, Inc.
• Metabiomics Corporate
• Synthetic Biologics, Inc.
• DuPont
• BiomX Ltd.

North America Human Microbiome Report Scope

Report Attribute Details
Market size in 2017 US$ 113.88 Million
Market Size by 2025 US$ 446.39 Million
CAGR (2018 - 2025) 21.5%
Historical Data 2015-2016
Forecast period 2018-2025
Segments Covered By Product
  • Probiotics
  • Foods
  • Prebiotics
  • Medical Foods
  • Diagnostic Device
  • Drugs
  • Supplements
By Disease
  • Obesity
  • Diabetes
  • Autoimmune Disorders
  • Cancer
  • Mental Disorders
By Application
  • Therapeutics and Diagnostics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • Enterome
  • MicroBiome Therapeutics, LLC
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Metabiomics Corporate
  • Synthetic Biologics, Inc.
  • DuPont
  • BiomX Ltd.
Trupti Wadekar
Assistant Manager,
Market Research & Consulting

Trupti is a senior consultant with over 10 years of experience in the Healthcare sector, specializing in pharmaceuticals, biotechnology, and life-sciences markets. She holds a Bachelor’s degree in Biotechnology and an MBA with dual specialization in Marketing and Pharmaceuticals & Biotechnology, combining a strong scientific foundation with a strategic and commercial perspective. Her professional experience encompasses market research, competitive intelligence, strategic advisory, and business development, supporting clients across diverse and evolving healthcare markets.

She has worked extensively on market sizing and assessment, growth strategy, market expansion, and strategic decision-making initiatives, helping clients identify opportunities and address complex business challenges. Trupti brings strong expertise in client engagement, stakeholder management, team leadership, and translating research findings into actionable business insights. Her ability to connect scientific understanding with market dynamics and commercial strategy enables her to deliver practical, high-impact solutions aligned with client objectives.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA